Champions Oncology, Inc. (CSBR) Q3 2025 Earnings Call Transcript

2025-03-11 20:07:06 ET

Champions Oncology, Inc. (CSBR)

Q3 2025 Earnings Conference Call

March 11, 2025 04:30 PM ET

Company Participants

Ronnie Morris - CEO

David Miller - CFO

Conference Call Participants

Maj Soueidan - GeoInvesting

George Marema - Pareto Ventures

Presentation

Operator

Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions]. Please note, this conference is being recorded. I will now turn the conference over to your host, Ronnie Morris, Chief Executive Officer. You may begin.

Ronnie Morris

Good afternoon. I am Ronnie Morris of Champions Oncology. Joining me today is David Miller, our Chief Financial Officer. Thank you for joining us for our quarterly earnings call. Before I begin, I'll remind you that we'll be making forward-looking statements during today's call and that actual results could differ materially from what is described in those statements. Additional information on factors that could cause results to differ is available on our Forms 10-Q and Form 10-K. A reconciliation of non-GAAP financial measures that may be discussed during the call to GAAP financial measures is available in the earnings release. Q3 marked a transformative quarter for Champions Oncology, underscored by our record revenue of $17 million and the successful closure of our inaugural data deal. Our core services business remains at the forefront, driven by our industry leading PDX bank and its precisely characterized multiomic data, which has become the foundation for the pharmacology studies that have been used broadly by the biopharma industry. Throughout the year, we have dedicated ourselves to strengthening our teams and refining our processes, resulting in enhanced quality, increased efficiency and scalability, which in turn have led to improved cost management and profitability. As we look ahead, we maintain a cautiously optimistic outlook for a rebound in our industry sector with customers beginning to expand their R&D budgets and a slight recovery in the capital raising environment for biotech industry.

Despite the mild improvement in the sector, the environment remains tight, leading to potential performance volatility. However, the overall trend suggests promising opportunities for long term growth. A significant a differentiator for Champions has always been our PDX bank, offering pharmaceutical and biotech companies invaluable insights for drug development. By consistently expanding our collection of unique tumor models and enhancing their characterization, we have developed a robust multiomic data set with substantial potential for both drug discovery and development. This data set serves as a vital resource for our pharma partners who gain access to model specific data. With the rise of AI which can extract deeper insights from the biological data, the demand for our data set has notably increased in both breadth and depth. Recognizing this shift, we are actively exploring ways to extract greater value from this data. The recently closed data deal exemplifies our strategic vision where we licensed our existing deep multiomic data set while also acquiring prospective omic data sets from our unique bank of tumor models. This continued expansion of our data set aligns with our mission to create the world's most comprehensive biological data set from a clinically relevant tumor population. Such a data set aims to bridge the gaps in existing data using -- used for AI and ML mediated discovery workflows, ultimately transforming how the biopharmaceutical industry approaches target and biomarker discovery as well as pipeline management. Over the past few years, we have worked diligently to enhance this data platform, pioneering the use of deep multiomic data sets in oncology discovery. The biopharmaceutical sector is now recognizing the immense untapped value within this type of data set, shifting away from classical data sets that offer broad insights but lack depth....

Read the full article on Seeking Alpha

For further details see: